January 2025

Next Phase in NF1 Biomarker Research Targets Early Cancer Detection

The Children’s Tumor Foundation (CTF), in collaboration with CureNFwithJack (CNFWJ), is proud to announce the next phase of an innovative biomarker project aimed at revolutionizing the detection and monitoring of cancerous tumors in patients with NF1. Building on earlier groundbreaking research funded by CTF, this non-invasive approach holds tremendous promise for revolutionizing cancer detection. For NF1 patients, it offers life-changing benefits, including the potential for earlier detection, less invasive monitoring, and improved outcomes. By identifying cancer before symptoms arise, this approach enables proactive intervention. It reduces the need for surgeries and frequent imaging scans, making monitoring less burdensome. Most importantly, it paves the way for personalized treatment plans and allows for earlier action when tumors show signs of becoming cancerous.

Read More

NF Knowledge Series: NF1 Cognitive Research

CTF is proud to launch a new monthly webinar series for families and individuals living with any form of NF. Join us each month to hear the latest NF research and expert guidance on clinical care issues.

Thursday, January 23 | 3:00 p.m. ET
Dr. Yang Hou is an assistant professor in the Department of Behavioral Sciences and Social Medicine and Director of the Development, Equity, and Resilience (DEaR) Lab at the College of Medicine, Florida State University. Her work focuses on the cognitive health of both adolescents and adults with NF1. Join us to hear about her latest research studies and how you can get involved.

RSVP

See the Early-Stage Clinical Projects Bringing Us Closer to Better Treatments

CTF's Clinical Research Awards (CRA) have supported early-stage pilot clinical trials and interventions for NF1, schwannomatosis, and NF2-related schwannomatosis since 2008. We invite you to read more about these projects and the critical role each researcher plays in our collective mission to improve the lives of those affected by NF. 

View 2024 Awardees

CTF Invests Nearly $1M in New Round of Drug Discovery for Most Challenging NF Manifestations

The Children’s Tumor Foundation is pleased to announce a significant investment of more than $995,000 in Drug Discovery Initiative (DDI) Awards focused on drug discovery for the most challenging manifestations of neurofibromatosis type 1 (NF1), pain in schwannomatosis (SWN), and vestibular schwannomas in patients with NF2-related schwannomatosis (NF2-SWN). Learn more about the 2024 DDI awardees and their projects.

View 2024 Awardees

Story of NF: Abbi E.

I was diagnosed with NF2-related schwannomatosis entirely incidentally at age 16. I went to my optometrist for an annual eye exam. In less than two months, I went from being a typical junior in high school to having a life-changing diagnosis and a spinal cord injury. This experience has taught me the value of living in the moment because you can never know what tomorrow may hold.

Read More
Facebook
Twitter
Instagram
YouTube
LinkedIn
CTF NEWSFEED   |  DONATE